-

Artificial Intelligence In Remote Patient Monitoring Market Research Report 2022 - Global Forecast to 2027 - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence In Remote Patient Monitoring Market Research Report by Product, Solution, Technology, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Artificial Intelligence In Remote Patient Monitoring Market size was estimated at USD 892.99 million in 2021, USD 1,121.16 million in 2022, and is projected to grow at a CAGR 25.72% to reach USD 3,527.32 million by 2027.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Cumulative Impact of COVID-19:

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

Market Share Analysis:

Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Market Dynamics

Drivers

  • ICT infrastructure development in developing countries
  • Rise in adoption of AI in remote patient monitoring due to real time monitoring and improved patient engagement
  • Growth in demand due to optimizing management and lower human errors

Restraints

  • Lack of awareness in remote areas
  • Expensive as compared to traditional facilities

Opportunities

  • Rapid digitalization and extensive use of social media of consumer
  • Shift in trend towards wearable technology

Challenges

  • Increasing concern related to cybersecurity and privacy

Cumulative Impact of COVID-19

Companies Mentioned

  • 100 Plus
  • AiCure
  • Binah.ai
  • Biofourmis
  • Cardiomo
  • ChroniSense Medical
  • ContinUse Biometrics (Cu-Bx)
  • Current Health
  • Ejenta
  • Eko
  • Engagely.ai
  • Feebris
  • GYANT
  • iHealth
  • Medical Device + Diagnostic Industry (MD+DI)
  • Medopad
  • Myia
  • Neoteryx, LLC
  • Neteera
  • Tech Vedika
  • ten3T Healthcare
  • Vitls

For more information about this report visit https://www.researchandmarkets.com/r/d3whs1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

United States Semaglutide Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, Eli Lilly and Co, AstraZeneca, Biocon, Johnson and Johnson, Pfizer, AbbVie, and Sanofi - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Semaglutide Market Report by Product, Application, Distribution Channel, States and Company Analysis, 2025-2033" report has been added to ResearchAndMarkets.com's offering. United States Semaglutide Market is expected to expand from US$ 8.17 Billion in 2024 to US$ 17.29 Billion in 2033 at a Compound Annual Growth Rate (CAGR) of 8.68% during 2025-2033 The growth is fueled by rising awareness regarding obesity control, increasing incidence of diabetes,...

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% The report will help market leaders/new...

Liraglutide and Semaglutide Global Strategic Business Analysis Report 2025-2030: Regulatory Pipeline for Pediatric and Adolescents With Obesity Creates Long-Term Market Opportunities - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Liraglutide and Semaglutide - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Liraglutide and Semaglutide was valued at US$17.1 Billion in 2024 and is projected to reach US$29.8 Billion by 2030, growing at a CAGR of 9.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Liraglutide and s...
Back to Newsroom